poisar

Stocks · News reference

J.P. Morgan Maintains Buy Rating and Sets $70 Price Target for First Tracks Biotherapeutics

Fiscal.ai

J.P. Morgan analyst Anupam Rama has reaffirmed a 'Buy' rating on First Tracks Biotherapeutics, Inc. (TRAX) and established a price target of $70.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading